JP Morgan Chase Portfolio holdings
JPMorgan Chase & Co., formed by the 2000 merger of J.P. Morgan & Co. and Chase Manhattan Bank, is a global financial services giant headquartered in New York City, tracing its roots back to 1799 through its predecessor firms. As one of the largest banks in the world, it operates across investment banking, commercial banking, asset management, and consumer banking, managing trillions in assets and serving millions of customers, corporations, and governments. Led by CEO Jamie Dimon since 2005, the firm is renowned for its role in high-profile deals, robust trading operations, and its Chase retail banking network, which includes extensive credit card and mortgage services. Combining a legacy of financial innovation with a dominant market presence, JPMorgan Chase remains a cornerstone of the global economy.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares 0-1 Year Treasury Bond ETF
SHV
|
+$3.85B |
| 2 |
iShares Core US Aggregate Bond ETF
AGG
|
+$1.5B |
| 3 |
JPMorgan BetaBuilders Canada ETF
BBCA
|
+$1.21B |
| 4 |
Chevron
CVX
|
+$1.08B |
| 5 |
JPMorgan BetaBuilders Europe ETF
BBEU
|
+$986M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares 1-3 Year Treasury Bond ETF
SHY
|
+$3.61B |
| 2 |
Occidental Petroleum
OXY
|
+$1.36B |
| 3 |
Merck
MRK
|
+$913M |
| 4 |
Visa
V
|
+$801M |
| 5 |
AT&T
T
|
+$771M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 27.95% |
| 2 | Technology | 12.9% |
| 3 | Financials | 12.36% |
| 4 | Healthcare | 9.31% |
| 5 | Consumer Discretionary | 8.69% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
4426
PetMed Express
PETS
$28.6M
| $228K | ﹤0.01% |
14,389
-40,416
| -74% | -$795K |
2015 Q4
14 quarters
|
|
|
THR
4427
DELISTED
Thermon Group Holdings
THR
| $228K | ﹤0.01% |
8,930
-2,980
| -25% | -$74.3K |
2017 Q4
6 quarters
|
|
4428
Team
TISI
$130M
| $227K | ﹤0.01% |
1,487
+150
| +11% | +$24.2K |
2013 Q2
24 quarters
|
|
4429
Corvus Pharmaceuticals
CRVS
$903M
| $226K | ﹤0.01% |
66,687
-100,434
| -60% | -$393K |
2016 Q2
12 quarters
|
|
4430
First Trust Dorsey Wright International Focus 5 ETF
IFV
$217M
| $226K | ﹤0.01% |
11,515
-1,680
| -13% | -$32.4K |
2017 Q1
9 quarters
|
|
4431
Chefs' Warehouse
CHEF
$4.53B
| $225K | ﹤0.01% |
6,632
+1,327
| +25% | +$43.7K |
2017 Q4
6 quarters
|
|
4432
AXT Inc
AXTI
$5.68B
| $224K | ﹤0.01% |
57,545
+48,263
| +520% | +$226K |
2017 Q3
7 quarters
|
|
4433
Vericel Corp
VCEL
$2.1B
| $224K | ﹤0.01% |
12,078
-4,276
| -26% | -$72.9K |
2018 Q1
5 quarters
|
|
|
CVIA
4434
DELISTED
Covia Holdings Corporation Common Stock
CVIA
| $224K | ﹤0.01% |
115,319
+103,260
| +856% | +$398K |
2018 Q2
4 quarters
|
|
4435
Mesa Laboratories
MLAB
$796M
| $222K | ﹤0.01% |
937
+116
| +14% | +$27K |
2017 Q4
6 quarters
|
|
|
BREW
4436
DELISTED
Craft Brew Alliance, Inc.
BREW
| $222K | ﹤0.01% |
15,806
+8,180
| +107% | +$117K |
2017 Q3
7 quarters
|
|
4437
Northern Trust Morningstar Global Upstream Natural Resources ETF
GUNR
$6.98B
| $221K | ﹤0.01% |
6,750
+2,927
| +77% | +$94.8K |
2018 Q2
4 quarters
|
|
4438
Duluth Holdings
DLTH
$156M
| $220K | ﹤0.01% |
15,866
-7,172
| -31% | -$116K |
2017 Q3
7 quarters
|
|
4439
FB Financial Corp
FBK
$2.63B
| $220K | ﹤0.01% |
6,127
-326
| -5% | -$11.5K |
2016 Q4
10 quarters
|
|
4440
Embotelladora Andina Series B
AKO.B
$4.69B
| $219K | ﹤0.01% |
10,082
-3,477
| -26% | -$73.6K |
2018 Q4
2 quarters
|
|
4441
Home Bancorp
HBCP
$530M
| $219K | ﹤0.01% |
5,997
-395
| -6% | -$14.3K |
2017 Q3
7 quarters
|
|
|
KNDI
4442
PUT
Kandi Technologies Group
KNDI
$70.8M
| $218K | ﹤0.01% |
44,900
-81,400
| -64% | -$414K |
2019 Q1
1 quarter
|
|
4443
Rafael Holdings
RFL
$76.4M
| $218K | ﹤0.01% |
8,023
-7,998
| -50% | -$138K |
2018 Q1
5 quarters
|
|
|
GCAP
4444
PUT
DELISTED
Gain Capital Holdings, Inc.
GCAP
| $218K | ﹤0.01% |
+54,000
| New | +$260K |
2019 Q2
0 quarters
|
|
|
AGS
4445
DELISTED
PlayAGS
AGS
| $217K | ﹤0.01% |
11,326
-24,456
| -68% | -$526K |
2018 Q1
5 quarters
|
|
4446
State Street SPDR S&P Health Care Services ETF
XHS
$225M
| $217K | ﹤0.01% |
3,300
-12,076
| -79% | -$777K |
2018 Q1
5 quarters
|
|
4447
Madrigal Pharmaceuticals
MDGL
$11.4B
| $216K | ﹤0.01% |
2,146
+461
| +27% | +$49.4K |
2017 Q3
7 quarters
|
|
4448
ProShares S&P 500 Dividend Aristocrats ETF
NOBL
$11B
| $216K | ﹤0.01% |
6,268
-622,494
| -99% | -$21.2M |
2016 Q1
13 quarters
|
|
4449
CALL
Novavax
NVAX
$2.07B
| $216K | ﹤0.01% |
35,000
-500
| -1% | -$3.94K |
2019 Q1
1 quarter
|
|
4450
Superior Group of Companies
SGC
$207M
| $215K | ﹤0.01% |
12,505
+485
| +4% | +$8.28K |
2017 Q4
6 quarters
|
|
Similar funds
JP Morgan Chase's Q2 2019 Portfolio in Review
As of Q2 2019, JP Morgan Chase held 6,226 positions worth $511B, up 4.5% from $490B the previous quarter. Its ten largest holdings account for 16% of the portfolio.
JP Morgan Chase's Q2 2019 filing shows 458 new, 2,668 increased, 2,116 reduced and 420 closed positions. Its largest new stake was Corteva: 13,119,143 shares worth $388M. The largest sale was iShares 1-3 Year Treasury Bond ETF, an estimated $3.61B.
By sector, the portfolio is most concentrated in Miscellaneous at 28% of assets, up from 27% a quarter earlier, followed by Technology and Financials.
- JP Morgan Chase's largest Q2 2019 buy was Corteva: 13,119,143 shares worth $388M.
- JP Morgan Chase added most to iShares 0-1 Year Treasury Bond ETF in Q2 2019, an estimated $3.85B increase.
- JP Morgan Chase's biggest Q2 2019 reduction was iShares 1-3 Year Treasury Bond ETF, cutting an estimated $3.61B.
- JP Morgan Chase fully exited Goldcorp Inc in Q2 2019, selling an estimated $131M.
- JP Morgan Chase's ten largest holdings make up 16% of its $511B portfolio in Q2 2019.
- JP Morgan Chase opened 458 new positions and closed 420 in Q2 2019.
- JP Morgan Chase's portfolio value rose 4.5% quarter-over-quarter to $511B.
Based on JP Morgan Chase's 13F filing for Q2 2019, filed 7 Aug 2019.